Condition: Advanced Melanoma · Sponsor: Memorial Sloan Kettering Cancer Center
The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma.
This description comes directly from the study's public registry record.
James Smithy, MD · 646-888-6782 · smithyj@mskcc.org
Michael Postow, MD · 646-888-4589
Always discuss trial participation with your own doctor first.
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Stanford University (Data Collection Only) | Stanford, California, United States | Recruiting |
| Hartford Healthcare Alliance (Data Collection Only) | Hartford, Connecticut, United States | Recruiting |
| Memorial Sloan Kettering Basking Ridge (All Protocol Activities) | Basking Ridge, New Jersey, United States | Recruiting |
| Hackensack Meridian Health (Data Collection Only) | Hackensack, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth (All Protocol Activities) | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester (All Protocol Activities) | Harrison, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale, New York, United States | Recruiting |
| MD Anderson Cancer Center (Data Collection Only) | Houston, Texas, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06594991